Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib combinations in advanced TNBC
NCT04464174Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ipatasertib in triple-negative breast cancer (TNBC), sponsored by MEDSIR. Started Oct 2020; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04464174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464174.